Immunoglobulin News and Research

RSS

Study supports single-dose COVID-19 vaccine strategy for previously infected individuals

Researchers in the Netherlands have provided evidence that a single dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine is sufficient to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people who have already been infected with the virus.

28 May 2021

Identifying SARS-CoV-2 epitopes targeted by current vaccination could help improve future vaccines

Researchers in the United States have identified antibody-inducing epitopes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals vaccinated against coronavirus disease 2019 (COVID-19) that could be used for future diagnostics, therapeutics, and vaccine design.

28 May 2021

Vagus nerve stimulation may be a potential adjunct therapy for COVID-19

COVID-19 was initially described as lung inflammation, or pneumonia, in older adults. However, we now know that SARS-CoV-2 infections can cause a wide range of symptoms in people of all ages, ranging from no symptoms at all to systemic inflammation and even death.

27 May 2021

Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group

A team of scientists from Canada and Spain recently evaluated the durability of antigen-specific immune responses in COVID-19 recovered individuals. They have also identified potential host factors associated with robust and long-lasting anti-SARS-CoV-2 immunity.

26 May 2021

Could GRP78 be a therapeutic target against COVID-19?

A new study by a team of researchers at the Keck School of Medicine, University of Southern California, USA, reports a potentially important therapeutic target in the form of a molecule called GRP78 that promotes the entry and protein production by many viruses. The team's paper has been published in the Journal of Biological Chemistry.

26 May 2021

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Recent COVID-19 investigations have found that up to half of immunocompromised individuals struggle to produce antibodies after receiving their severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations.

26 May 2021

Study shows how rare but serious post-COVID-19 complication develops in children, adolescents

A multidisciplinary team from MassGeneral Hospital for Children (MGHfC), Brigham and Women's Hospital and other institutions have identified the mechanism of how an extremely rare but serious post-COVID-19 complication develops in children and adolescents.

26 May 2021

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

The aim of this study investigates the impact of different types of vaccines on the anti-SARS-CoV-2 Immunoglobulin A (IgA) and Immunoglobulin G (IgG) antibody levels found in human milk.

25 May 2021

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Antibodies, Antibody, Assay, Coronavirus, Efficacy, Healthcare, Pandemic, Protein, Receptor, Research, Vaccine, Virus, Coronavirus Disease COVID-19,

24 May 2021

Memory B cells with a functional anti-SARS-CoV-2 response persist despite loss of specific IgG

In Munich, Germany, scientists at Ludwig Maximilian University studied temporal adaptive immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to better understand protection against re-infection. They found functional properties of persisting memory B specific to SARS-CoV-2 may help in protect against the virus.

23 May 2021

Risk factors for rare COVID-19 complications in children (MIS-C)

While the earlier waves of COVID-19 relatively spared children, some of the affected children have developed a systemic inflammatory condition, with occasionally fatal outcomes. Called multisystem inflammatory syndrome in children (MIS-C), its pathogenesis and risk factors are the subject of a new study on the medRxiv* preprint server.

21 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Are COVID-19-related complications in children explained by abnormal immune responses?

A common theme in reports on COVID-19 around the world has been the large number of children who have not been infected or shown signs of disease. However, though the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes less acute infection in this age group, it is associated with a severe immune-mediated multisystemic illness called multisystem inflammatory syndrome in children (MIS-C).

20 May 2021

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Researchers from Germany and the USA recently investigated the cellular and humoral immune responses of patients with IMIDs on immunomodulatory treatment to mRNA COVID-19 vaccines. The research is published on the medRxiv* preprint server.

19 May 2021

Milder COVID-19 in children may be due to higher memory B cells responses to SARS-CoV-2

A new research paper published in the journal Science explores the differences in coronavirus-specific B memory cell repertoires in children versus adults, as well as the functional importance of this discovery.

18 May 2021

COVID-19 mRNA vaccines safe and effective for pregnant and breastfeeding women

The current coronavirus disease 2019 (COVID-19) pandemic has brought untold devastation in its wake, with its rapid and asymptomatic spread to hundreds of millions of people the world over. Vaccines have been hailed as the way out of this situation, and a dozen or so are being rolled out in many different countries.

18 May 2021

Breastfeeding safe and beneficial in SARS-CoV-2 infection

\With the onset of the coronavirus disease 2019 (COVID-19) pandemic, hundreds of millions of people became infected worldwide, including thousands of pregnant women near term. The question of vertical transmission to the infant via the placenta or breast milk was very real, leading to a near-total ban on breastfeeding in this group.

17 May 2021

Antibodies generated by malaria cross-react with SARS-CoV-2

An international team of researchers has warned that individuals with acute malaria infection generate high levels of antibodies that cross-react with the viral spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

13 May 2021

Immunoglobulin News and Research

Study supports single-dose COVID-19 vaccine strategy for previously infected individuals

Identifying SARS-CoV-2 epitopes targeted by current vaccination could help improve future vaccines

Vagus nerve stimulation may be a potential adjunct therapy for COVID-19

Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group

Could GRP78 be a therapeutic target against COVID-19?

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Study shows how rare but serious post-COVID-19 complication develops in children, adolescents

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Memory B cells with a functional anti-SARS-CoV-2 response persist despite loss of specific IgG

Risk factors for rare COVID-19 complications in children (MIS-C)

Facets of SARS-CoV-2 infection and animal models

Are COVID-19-related complications in children explained by abnormal immune responses?

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Milder COVID-19 in children may be due to higher memory B cells responses to SARS-CoV-2

COVID-19 mRNA vaccines safe and effective for pregnant and breastfeeding women

Breastfeeding safe and beneficial in SARS-CoV-2 infection

Antibodies generated by malaria cross-react with SARS-CoV-2

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News